The National Institute for Health and Care Excellence

New technologies could help cut years-long wait for endometriosis diagnosis

Endometriosis affects around 1 in 10 women of reproductive age in the UK, yet the average time to diagnosis is more than 9 ...
The National Institute for Health and Care Excellence

New draft PMOS guideline recommends annual review and could mean quicker diagnosis

People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, ...
The National Institute for Health and Care Excellence

Novel life-saving liver procedure recommended, potentially enabling hundreds more transplants

It’s the first time a NICE committee has reviewed the evidence behind the procedure which preserves the donor liver by pumping oxygenated blood through it using a machine for around two hours. This ...
National Institute for Health and Care Excellence

Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor

There is a simple discount patient access scheme for pirtobrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Quality statement 6: Primary PCI for acute STEMI

Adults with acute ST-segment-elevation myocardial infarction (STEMI) who present within 12 hours of onset of symptoms have primary percutaneous coronary intervention (PCI), as the preferred coronary ...
National Institute for Health and Care Excellence

Acne vulgaris: management

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...
National Institute for Health and Care Excellence

Dementia: assessment, management and support for people living with dementia and their carers

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
National Institute for Health and Care Excellence

Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency

Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch ...
National Institute for Health and Care Excellence

Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults. There is a commercial access ...
National Institute for Health and Care Excellence

Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment

We have moved Health technology evaluation 3 to become HealthTech guidance 660. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...
National Institute for Health and Care Excellence

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...